Effectiveness of botulinum toxin B in the treatment of drooling
Review articleOpen access
Abstract:

AbstractThe aim of this audit was to assess the effectiveness of botulinum toxin B (NeuroBloc®, Eisai Ltd.) in the treatment of drooling. Over a period of 18 months patients treated with NeuroBloc® botulinum toxin (BTX) for serious drooling (drooling score more than 7) were invited to complete a questionnaire on their experience of drooling and the impact of treatment. A total of 170 questionnaires were given to consecutive patients or carers and 145 (85%) responded. Of these, 128 (88%) reported that symptoms had improved by 6/10 or more on a visual analogue scale (VAS), and 54 (37%) reported compete resolution of drooling (10/10 VAS). A total of 139 (96%) would recommend the treatment to others.

Request full text

References (0)

Cited By (0)

No reference data.
No citation data.
Advertisement
Join Copernicus Academic and get access to over 12 million papers authored by 7+ million academics.
Join for free!